Published in Pigment Cell Melanoma Res on February 14, 2009
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett (2010) 1.18
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol (2010) 1.02
Interleukin-8 in breast cancer progression. J Interferon Cytokine Res (2013) 1.00
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (2012) 0.99
Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog (2011) 0.99
The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. Cancer Microenviron (2011) 0.98
Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res (2012) 0.95
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Cell Death Differ (2010) 0.92
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets (2010) 0.89
Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun (2009) 0.88
Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. J Cancer (2015) 0.87
Inflammation and tumor microenvironment in lymph node metastasis. Cancers (Basel) (2011) 0.85
Retinoid-X-receptors (α/β) in melanocytes modulate innate immune responses and differentially regulate cell survival following UV irradiation. PLoS Genet (2014) 0.83
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget (2016) 0.83
Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol (2011) 0.82
Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation. BMC Cancer (2014) 0.81
CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clin Exp Metastasis (2012) 0.81
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med (2012) 0.80
IL-18 regulates melanoma VLA-4 integrin activation through a Hierarchized sequence of inflammatory factors. J Invest Dermatol (2013) 0.77
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-α expression levels. Oncotarget (2016) 0.77
Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. Oncoimmunology (2015) 0.77
Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts. BMC Cancer (2015) 0.76
Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. Cancers (Basel) (2012) 0.76
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget (2017) 0.75
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. Bioorg Med Chem (2015) 0.75
Melanocyte and melanoma cell activation by calprotectin. J Skin Cancer (2014) 0.75
Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res (2016) 0.75
Mechanisms of CXCR7 induction in malignant melanoma development. Oncol Lett (2017) 0.75
Mechanistic insights into molecular evolution of species-specific differential glycosaminoglycan binding surfaces in growth-related oncogene chemokines. R Soc Open Sci (2017) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Control of chemokine-guided cell migration by ligand sequestration. Cell (2008) 4.61
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells (2005) 4.06
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol (2004) 3.50
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol (2007) 3.25
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
Cancer: Inflaming metastasis. Nature (2009) 3.09
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol (2002) 2.81
Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst (2001) 2.64
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44
The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol (2006) 2.42
Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med (2007) 2.29
The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol (2002) 2.27
How chemokines invite leukocytes to dance. Nat Immunol (2008) 2.18
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol (1997) 2.15
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest (2006) 2.14
Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13
Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res (2008) 2.08
Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int J Cancer (1997) 2.08
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol (2006) 2.03
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun (2007) 1.96
Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res (2009) 1.93
Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene (1991) 1.88
Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol (1996) 1.86
Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res (2001) 1.79
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol (1997) 1.72
Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.71
Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation (2003) 1.71
Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology (1999) 1.70
A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res (2006) 1.66
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis (2007) 1.63
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia (2008) 1.60
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60
CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res (2003) 1.57
BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res (2006) 1.54
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res (2004) 1.50
Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol (2005) 1.49
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol (2007) 1.49
Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun (1990) 1.48
The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol (2000) 1.48
Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis. Oncogene (2006) 1.44
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 1.43
Chemokines as mediators of angiogenesis. Thromb Haemost (2007) 1.40
Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol (2006) 1.39
Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis (2003) 1.39
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res (2006) 1.37
Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol (1992) 1.33
The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J (2006) 1.33
Chemokine receptors and melanoma metastasis. J Dermatol Sci (2004) 1.32
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst (2008) 1.29
Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res (2006) 1.26
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol (2008) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol (2006) 1.22
Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther (2008) 1.21
Retracted Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer (2008) 1.21
Chemokine blockers--therapeutics in the making? Trends Pharmacol Sci (2005) 1.21
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res (2006) 1.17
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 1.17
Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol (1992) 1.17
The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol (2009) 1.17
Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res (2006) 1.17
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics (2006) 1.14
Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw (2007) 1.13
The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J (2002) 1.12
Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res (2007) 1.11
Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J (2003) 1.09
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther (2006) 1.07
The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther (2004) 1.06
Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res (2005) 1.06
C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res (2005) 1.05
Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther (2007) 1.05
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother (2007) 1.04
CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol (2005) 1.03
Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol (2007) 1.03
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res (2005) 1.03
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res (2007) 1.02
Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol (2006) 1.02
Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res (2007) 1.02
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol (2008) 1.02
Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res (2006) 1.01
A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun (2004) 1.01
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology (2003) 1.67
The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res (2005) 1.57
Fenitrothion: toxicokinetics and toxicologic evaluation in human volunteers. Environ Health Perspect (2003) 1.48
Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One (2010) 1.29
Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw (2007) 1.13
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol (2007) 1.10
Wnt/β-catenin pathway forms a negative feedback loop during TGF-β1 induced human normal skin fibroblast-to-myofibroblast transition. J Dermatol Sci (2011) 1.03
Intracellular localization of differentially regulated RNA-specific adenosine deaminase isoforms in inflammation. J Biol Chem (2003) 1.01
Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med (2007) 0.97
How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found Symp (2004) 0.94
Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol (2003) 0.93
Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells. J Biol Chem (2012) 0.93
The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol (2012) 0.92
The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem (2008) 0.91
Subcellular distribution of ADAR1 isoforms is synergistically determined by three nuclear discrimination signals and a regulatory motif. J Biol Chem (2004) 0.89
Identification of new targets of Drosophila pre-mRNA adenosine deaminase. Physiol Genomics (2004) 0.87
CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res (2007) 0.83
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. J Leukoc Biol (2008) 0.79
Enhancement of fat graft survival by bone marrow-derived mesenchymal stem cell therapy. Plast Reconstr Surg (2013) 0.79
Bone marrow transplantation combined with mesenchymal stem cells induces immune tolerance without cytotoxic conditioning. J Surg Res (2011) 0.78
Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation (2003) 0.77
MOB-1 and TNF-alpha interact to induce microvascular lung injury. Shock (2002) 0.77
Investigation on the interaction behavior between curcumin and PAMAM dendrimer by spectral and docking studies. Spectrochim Acta A Mol Biomol Spectrosc (2013) 0.76
Morphological features of cell death and tissue remolding of fat grafts. Ann Plast Surg (2015) 0.76
The utilization of perforated bioinert chambers to generate an in vivo isolated space for tissue engineering involving chondrocytes, mesenchymal stem cells, and fibroblasts. Tissue Eng Part C Methods (2013) 0.75
[Effects of Angelica dahurica extracts on biological characteristics of human keratinocytes]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2012) 0.75
[An alternative model of composite tissue transplantation in rat: the femur osteomyocutaneous flap]. Zhonghua Zheng Xing Wai Ke Za Zhi (2014) 0.75
Study on the enzymatic degradation of PBS and its alcohol acid modified copolymer. Biodegradation (2011) 0.75
Comparison of Negative Pressure Wound Therapy and Conventional Therapy for Cranial Bone-exposed Wounds in Rabbits. Ann Plast Surg (2017) 0.75
Heat-Shock Protein 70 Overexpression in Adipose-Derived Stem Cells Enhances Fat Graft Survival. Ann Plast Surg (2017) 0.75
Identification of the Centrifuged Lipoaspirate Fractions Suitable for Postgrafting Survival. Plast Reconstr Surg (2016) 0.75
Reconstruction of cervical scar contracture using axial thoracic flap based on the thoracic branch of the supraclavicular artery. Ann Plast Surg (2014) 0.75
Inhibition of Lymphatic Drainage With a Self-Designed Surgical Approach Prolongs the Vascularized Skin Allograft Survival in Rats. Ann Plast Surg (2017) 0.75
A Mouse Model of Vascularized Skin Transplantation. Ann Plast Surg (2017) 0.75
Reconstruction of Large Postburn Facial-Scalp Scars by Expanded Pedicled Deltopectoral Flap and Random Scalp Flap: Technique Improvements to Enlarge the Reconstructive Territory. J Craniofac Surg (2017) 0.75